Hackensack, NJ – June 15, 2021 –Champions Oncology (NASDAQ: CSBR), a technology-enabled research organization announced today that they have entered into a strategic partnership with BGI Americas.

Through this partnership, BGI will now have access to Champions’ Lumin Bioinformatics platform, a revolutionary data interpretation tool, to display and deliver proteomics data to their clients. By leveraging Lumin, BGI’s customers will be able to gain novel insights from their proteomics data using unique multi-omic datasets assembled from over 25,000 cancer patients. Lumin Bioinformatics allows oncology scientists and bioinformaticians to analyze and visualize cancer model public and proprietary datasets to illuminate the cellular dynamics of cancer, through specialized modules such as gene signatures, network viewers, synergy plots and even gene dependency mapper tools using AI machine learning technology.

Hackensack, NJ – March 11, 2021 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery and development through data-driven research strategies and innovative pharmacology, biomarker and data platforms, today announced its financial results for the third fiscal quarter ended January 31, 2021.

Third Quarter and Recent Highlights:

• Delivered record quarterly revenue of $10.8 million, an increase of 20% year over year
• Reported non-GAAP income from operations, excluding stock-based compensation, depreciation and amortization, of $1.3 million
• Expanded Lumin Bioinformatics proprietary SaaS platform with proteomic module integration

HACKENSACK, NJ – January 19, 2021 9AM - Champions Oncology, Inc. (Nasdaq: CSBR), a leading global oncology technology company that is transforming drug discovery and development through data-driven research strategies, announced today a partnership with Code Ocean to expand the functionality of its SaaS program, Lumin Bioinformatics. The partnership between Champions and Code Ocean will focus on enhancements involved in data integration and sharing workflows within the Lumin platform.  Users will now be equipped with a robust methodology for centralizing, storing, and organizing large amounts of their own code and data within Lumin, while leveraging single tenant hosting.  Users will have the ability to upload this information directly or utilize Champions’ computational services to assist with integration.  This new functionality establishes an entire new use case for Lumin and facilitates a customized experience for our clients.  Importantly, users will now have a method for secure and rapid data sharing, creating a strong collaboration workflow between scientists within their company.  These new applications transform Lumin into an enterprise-level solution, supporting Champions’ efforts to broaden the total available market.

HACKENSACK, NJ – January 5, 2021 8:30AM - Champions Oncology, Inc. (Nasdaq: CSBR), a leading global oncology technology company that is transforming drug discovery and development through data-driven research strategies, announced today the expansion of its SaaS program, Lumin Bioinformatics. Since its launch, Champions has been adding to the data and functionality housed within Lumin, which now features 20,000+ datasets including rare and valuable quantitative phospho-proteomics.  To aid in the analysis of this proteomic data, engineers at Champions have also developed a unique and sophisticated set of analysis tools that enable researchers to unlock the power of this proteomic data.

HACKENSACK, NJ / ACCESSWIRE / December 14, 2020 / Champions Oncology, Inc.

(NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery through innovative pharmacology, biomarker and data platforms, today announced its financial results for the second fiscal quarter ended October 31, 2020.

Second Quarter and Recent Highlights:

• Launched our Lumin Bioinformatics proprietary SaaS platform
• Delivered record quarterly revenue of $10.1 million, an increase of 33% year-over-year
• Reported income from operations, excluding stock-based compensation, depreciation and amortization, of $400,000
• Raising our full-year revenue guidance to 20%-25%

HACKENSACK, NJ / ACCESSWIRE / November 16, 2020 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider that is transforming drug discovery through innovative pharmacology, biomarker and data platforms, announced today the launch of its new proprietary SaaS program known as Lumin Bioinformatics. By leveraging Champions' large cancer dataset, which is unique for its substantial depth of characterization, combined with many other published cancer datasets, Lumin provides users with a vast database of tumor characterization that can be used for computational research. The software, which is purchased as a yearly subscription, also provides sophisticated analytic tools that are utilized to interrogate the data for associations between molecular and various phenotypic features, including thousands of drug responses, clinical annotations, prior treatment histories, and genetic dependencies. Insights developed using Lumin can provide the basis for biomarker hypotheses, reveal potential mechanisms of therapeutic resistance, and guide the direction of additional preclinical evaluations.

HACKENSACK, NJ / ACCESSWIRE / November 11, 2020 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider that is transforming drug discovery through innovative pharmacology, biomarker and data platforms, announced today the launch of a novel autologous immuno-oncology (IO) research platform. This autologous tumor infiltrating lymphocyte (TIL) ex vivo platform centers on the use of a tumor and an immune system derived from the same patient for investigations in the immuno-oncology space.

Hackensack, NJ – September 14, 2020 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the first fiscal quarter ended July 31, 2020.

Record Annual Revenue of $32.1 Million

HACKENSACK, NJ / ACCESSWIRE / July 27, 2020 / Champions Oncology, Inc. (NASDAQ:CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the year and fourth fiscal quarter ended April 30, 2020.

HACKENSACK, NJ / ACCESSWIRE / March 12, 2020 / Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the third fiscal quarter ended January 31, 2020.